Sanofi India | Business Upturn

Sanofi India Q2 Results: Revenue falls 9.3% YoY to Rs 475.4 crore, net profit down 7.5%

Aman Shukla — Wed, 29 Oct 2025 08:06:34 +0000

Sanofi India Limited reported its financial results for the quarter ended September 30, 2025, showing steady operational performance.

Revenue from operations stood at ₹475.4 crore, compared to ₹524 crore in the same quarter last year, reflecting a 9.3% year-on-year decline.

Despite softer revenue, the company maintained strong profitability, supported by cost optimization and improved efficiency across key segments. Net profit for the quarter came in at ₹76 crore, as against ₹82.2 crore in Q2 FY24.

EBITDA rose 12% year-on-year to ₹134 crore, compared to ₹120 crore in the same quarter last year. The company’s EBITDA margin improved sharply to 28.23%, up from 22.84% a year ago, reflecting better operational efficiency and cost control.

In the meantime, as of 1:37 PM, Sanofi India shares were trading 0.076% lower at Rs 4,744.80.

Disclaimer: This article is for informational purposes only. It is not intended to be investment advice or a recommendation to buy or sell any stock. Readers are advised to consult their financial advisor before making any investment decisions.

Sanofi India shares fall over 2% as Q1 revenue drops 12.4% YoY to Rs 406 crore, Ebitda down 18%

Aman Shukla — Fri, 01 Aug 2025 03:56:36 +0000

Sanofi India shares slipped more than 2% in early trade on Friday after the pharmaceutical major posted disappointing Q1 results for the financial year. The company’s revenue and operating margins declined year-on-year, sparking negative investor sentiment.

Q1 FY26 Financial Highlights (YoY)

In the quarter ended June 2025, Sanofi India reported a 12.4% drop in consolidated revenue to ₹406 crore, down from ₹464 crore in the same period last year. EBITDA also took a hit, falling 18% to ₹94.9 crore from ₹116 crore. Operating margins came in lower at 23.4%, compared to 25% a year ago.

Despite the revenue and EBITDA decline, net profit rose significantly to ₹69.5 crore, compared to just ₹10.3 crore in Q1 FY25.

Market Reaction

Sanofi India opened the day at ₹5,801 and touched an intraday low of ₹5,669, slipping over 2% from its previous close of ₹5,825. The stock continues to trade below its 52-week high of ₹7,600 but remains well above the 52-week low of ₹4,902.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Sanofi India Q4 Results: Net Profit declines 33.7% YoY, Revenue up 9.7% to Rs 514.9 crore

Aditya Bhagchandani — Thu, 27 Feb 2025 16:41:21 +0000

Sanofi India Limited has announced its Q4 financial results, reporting a 33.7% YoY decline in net profit to ₹91.3 crore, compared to ₹137.7 crore in the same period last year. Meanwhile, revenue increased by 9.7% to ₹514.9 crore from ₹469.2 crore YoY.

Key Financial Highlights:

Net Profit: ₹91.3 crore, down 33.7% YoY
Revenue: ₹514.9 crore, up 9.7% YoY
EBITDA: ₹118.3 crore, up 18.8% YoY
EBITDA Margin: 23% vs 21.2% YoY
Final Dividend: ₹117 per share

The company attributed its revenue growth to double-digit expansion in its diabetes portfolio, particularly with Toujeo® and Soliqua®, reinforcing confidence in its product offerings. It also emphasized new partnerships in the Cardiovascular (CV) and Central Nervous System (CNS) categories, which are expected to drive further growth.

Rodolfo Hrosz Managing Director, Sanofi India:

“In a year of significant transformation for the company, we have successfully brought to market Soliqua® – our best-in-class diabetes drug for the premix segment, which has received encouraging acceptance. Our efforts of reaching more HCPs through partnerships for the Cardiovascular and CNS (Central Nervous System) categories have advanced as planned, with initial promising results. We will continue to focus on driving further improvement in operating efficiencies while expanding the availability of established and innovative products in India.”

Sanofi India has continued its ‘India for India’ strategy, focusing on go-to-market initiatives, operational efficiency, and innovation. Managing Director Rodolfo Hrosz highlighted that Soliqua® has seen strong acceptance, and the company remains committed to improving efficiency while expanding its product availability in India.

Sanofi India reports 16% drop in net profit

Aditya Bhagchandani — Fri, 26 Jul 2024 12:27:18 +0000

Sanofi India Ltd. reported a 16% decrease in net profit for the first quarter of FY24, with earnings falling to ₹103.2 crore. This is down from ₹123 crore in the same quarter last year.

Revenue from operations also saw a decline, dropping 10% to ₹463.5 crore from ₹515 crore a year ago. Operating profit, or EBITDA, fell by 4.8% to ₹115.7 crore, although the EBITDA margin improved slightly to 25% from 23.6% in the previous year.

Despite these challenges, Sanofi India’s diabetes brands, Lantus and Toujeo, experienced double-digit growth in secondary sales, outperforming the market. The company also highlighted positive prospects for its new partnerships in the central nervous system and cardiovascular segments.

Net sales of ₹429 crore for the quarter are not fully comparable due to supply constraints and divestments in the previous year. However, these issues are expected to be resolved in the latter half of 2024.

Operating expenses were reduced by 9%, reflecting efforts to improve efficiency. Nonetheless, the profit before tax was affected by ₹19 crore in restructuring costs, leading to a reported profit before tax of ₹68 crore for the quarter.

Sanofi shares surge over 2% on partnership with Cipla for CNS product distribution

Aditya Bhagchandani — Wed, 27 Mar 2024 04:20:32 +0000

As part of a deal that will redefine the pharmaceutical realm, Sanofi India and Cipla have reached an agreement to operate in a limited partnership distribution and marketing for Sanofi’s Central Nervous System (CNS) Products line in India.

Cipla will now control the distribution of Sanofi India’s six CNS trademarks, which include the popular anti-epilepsy drug Frisium. This partnership represents an important move towards broader provision for patients across the nation to have access to essential healthcare solutions.

The shares of both Cipla and Sanofi India witnessed a surge in early trade on March 27 following the announcement. As of 9:45 am, Cipla shares were trading at ₹1,473.45, while Sanofi shares saw an increase of over 2% trading at ₹7,882.75.

This strategic alliance underscores the commitment of both companies to leverage their expertise and resources to address the evolving healthcare needs of the Indian populace. By combining Cipla’s extensive distribution network with Sanofi’s innovative CNS product portfolio, the partnership aims to make a meaningful impact on patient care and well-being.

Stocks to watch: HDFC Bank, Infosys, Zee Entertainment, Axis Bank and others

Aryan Jakhar — Fri, 24 Feb 2023 03:15:00 +0000

The Nifty futures contract traded on the Singapore Exchange shows that local equities are off to a good start. The contract was worth 17,644.50 at the time of writing, up 53.5 points or 0.30% from the previous close.

ZEEL: Zee Enterprises’ managing director and chief executive Puneet Goenka filed an appeal with the National Company Law Tribunal on Thursday, appealing the National Company Law Tribunal’s ruling admitting an IndusInd Bank application for insolvency proceedings against the corporation. On Thursday, the stock dropped more than 10% intraday before recovering to close 3.46% down.

Lemon Tree Hotels: The business authorised the purchase of up to 22,00,000 Compulsory Convertible Preference Shares in Aleur Hotels from APG Strategic Real Estate Pool N.V, an existing stakeholder.

HDFC Bank: The private sector lender announced a $750 million dollar bond offering. The bank issued $750 million in Senior Unsecured Bonds through its GIFT City IFSC Banking Unit. Moody’s Rating Services assigns the notes a Baa3 rating, while S&P assigns a BBB- rating.

Muthoot Finance: The company’s board of directors may evaluate and authorise fund raising through the issue of Non-Convertible Debentures (NCDs) via Private Placement.

Axis Bank: Last year, the lender announced plans to acquire Citibank’s India Consumer Business from Citibank N.A. as well as the NBFC Consumer Business from Citicorp Finance (India). It was disclosed in the discussions that they had made progress, receiving all of the essential clearances. The bank projected that the deal will be completed by March 1st.

Jindal Steel, Jindal Steel (Hisar): The NCLT approved the merger of Jindal Steel and Jindal Steel (Hisar) (Hisar). In a filing with the exchanges, the company stated that it had received the final order from NCLT sanctioning “the Composite Scheme of Arrangement under Section 66, 230-232, and other applicable provisions of the Companies Act, 2013, amongst Jindal Stainless, Jindal Stainless (Hisar), JSL Lifestyle, JSL Media, Jindal Stainless Corporate Management Services, and Jindal Lifestyle and their respective shareholders and creditors.”

Sanofi India: Sanofi India’s board of directors proposed a final dividend of Rs 194 per equity share, as well as a second special dividend of Rs 183 per equity share. The firm also declared a 44.8% increase in net profit year on year to Rs 130.8 crore for the quarter ending December 31, 2022.

Tube Investments of India bought 10,753 equity shares, representing 50% of X2Fuels and Energy’s subscribed and paid-up share capital. The firm is a start-up in its early stages that aims to develop and implement thermochemical technology for converting waste materials into storable liquid and solid fuels.

Titan: Titan’s subsidiary, Favre Leuba AG (FLAG), will aim to reduce activities in response to Titan’s board’s recommendations. FLAG will sell its “Favre Leuba” brand to a potential buyer. FLAG also indicated that it will apply for liquidation when the deal is completed, subject to getting the necessary clearances.

Bharat Forge: Bharat Forge announced that the ‘investment committee – defence business’ has approved the transfer of the company’s stake in Aeron Systems to Kalyani Strategic Systems, a wholly-owned subsidiary of the company, in order to house all of the company’s defense-related investments under one entity.

Infosys: Infosys announced an expansion of its relationship with Microsoft to assist expedite business cloud transformation journeys globally.

Stocks to watch: Adani Group, LIC, L&T, Tech Mahindra, Inox, GAIL and more

Aryan Jakhar — Tue, 31 Jan 2023 03:23:34 +0000

Domestic equity markets are anticipated to remain volatile on Tuesday as investors await the 2022–23 Economic Survey. In the run-up to the Union Budget announcement on Wednesday, February 1, fun might continue to be a significant emotion dictator today. At 7:40 a.m., the SGX Nifty was trading at 17,770, up 65 points.

Globally, the Nikkei, Straits Times, and Kospi opened flat on Tuesday. Overnight, US markets fell up to 2% ahead of the US Fed meeting, which starts later tonight, and major corporate results.

Here are the top stocks to watch on Tuesday, January 31:

Earnings today: ACC, Blue Star, Cholamandalam Investment and Finance Company, Coal India, Godrej Consumer Products, Indian Hotels, Indian Oil Corporation, Jindal Steel, KPIT Tech, Orient Bell, Orient Cement, Power Grid, RailTel, Star Health, Sunteck Realty, Venus Pipes and Tubes, Welspun Enterprises, and Westlife Foodworld are among the key companies set to report Q3FY23 earnings today.

Adani Group: Stock markets The circuit limitations for three Adani Group businesseshrAdani Total Gas, Adani Transmission, and Adani Green Energyiowere reduced from 20% to 10% on Monday by the BSE and NSE. The decision comes after a big sell-off in these equities in the previous three trading sessions caused a downward circuit.

LIC: The state-owned Life Insurance Corporation (LIC) would not invest more than Rs 300 crore in Adani Enterprise’s follow-on public offer (FPO), despite intentions to engage with the business group to seek clarity on claims made by Hindenburg Research.

Tech Mahindra (TechM): Tech Mahindra reported a 5.3 percent drop in net profit for the third quarter (Q3) of fiscal year 2022–23 (FY23) at Rs 1,297 crore. However, the overall contract value of the inked transactions was $795 million. This was an increase of 11% year over year. Another significant achievement for the corporation this quarter was the achievement of $1 billion in quarterly revenue for its enterprise segment.

L&T: Larsen & Toubro (L&T) announced a consolidated net profit of Rs 2,553 crore for the October-December quarter of 2022–23, up 24.2% from the previous year, bolstered by extraordinary profits of Rs 97 crore from the sale of the mutual fund business. L&T got orders worth Rs 60,710 crore during the quarter, representing a 21% increase over the same time last year.

Inox Leisure: Inox Leisure’s net loss for Q3 FY23 increased to Rs 40.42 crore from Rs 1.3 crore in the previous fiscal’s equivalent period. Revenue increased 74% to Rs 516 crore from Rs 296 crore, while costs increased by 63% to Rs 493 crore.

BPCL: After two consecutive quarters of losses, state-owned Bharat Petroleum Corporation (BPCL) declared a consolidated net profit of Rs 1,747 crore for the quarter ended December 31, 2022 (Q3FY23). In the third quarter, consolidated revenue from operations increased 13.67% to Rs 1.33 trillion.

Kansai Nerolac: Kansai Nerolac Paints has agreed to sell a nearly 24-acre property lot in Thane’s Kavesar to real estate developer House of Hiranandani Group for Rs 655 crore.

KEC International: The company said that it has received orders totaling Rs 1,131 crore from various sectors.

Alkem Laboratories: On Monday, Mumbai-based drugmaker Alkem released an antibiotic to treat numerous drug-resistant illnesses. According to the business, it was the first in India to offer a new antibiotic combination for treating drug-resistant diseases.

ADF Foods: ADF Foods’ consolidated net profit for Q3 FY23 was Rs 18.52 crore, compared to a net profit of Rs 13.3 crore YoY and Rs 13.6 crore QoQ. Its sales were Rs 123 crore, up from Rs 117 crore year over year and Rs 107 crore quarter over quarter.

Mangalore Chemicals: The company’s standalone net profit increased to Rs 76.2 crore from Rs 31.1 crore the previous year. In Q2 FY23, the firm reported a net loss of Rs 32 crore.

Sanofi India: After failing to obtain a UNICEF contract, French pharmaceutical company Sanofi SA is assessing operations at two of its vaccine manufacturing facilities in India and plans to lay off all staff, according to Reuters. A representative for Sanofi’s India branch told Reuters in an email that the company is providing voluntary retirement schemes (VRS) to all of its workers at two facilities near Hyderabad.

Nippon Life India AMC: Japan, India NAM India reported an 18% rise in profit after tax (PAT) at Rs 205 crore for Q3 FY23 on Monday. The previous year, the company reported a PAT of Rs 174 crore.

Punjab National Bank: Punjab National Bank on Monday assuaged worries about its exposure to Adani Enterprises by noting that its loans to the company are spread over 8–9 entities that generate enough income.

GAIL (India): GAIL (India) Ltd. on Monday reported a 90% reduction in December quarter net profit, at Rs 397.59 crore against Rs 3,800.09 crore YoY, due to losses in the petrochemical and natural gas marketing businesses. The country’s largest gas trading and transportation company lost Rs 349 crore in the petrochemical market owing to a reduction in supply of cheaper domestic gas.

Ultratech Cement: Ultratech Cement Middle East Investments Limited, the company’s wholly owned subsidiary in the UAE, has engaged in a Share Sale and Purchase Agreement with Seven Seas Company LLC, Oman, for the acquisition of 70% equity shares in Duqm Cement Project International, LLC, Oman.

Exide Industries: Exide Industries increased its consolidated net profit by 11.38 percent year on year (YoY) to Rs 198.61 crore in Q3FY23, owing to growth in most business verticals, pricing increases, and cost-cutting measures. The previous year’s profit was Rs 178.32 crore. Volume growth drove a 6.8 percent increase in revenue from operations to Rs 3,538.50 crore.

Stocks to watch: Adani Enterprises, Vi, Hero MotoCorp, Blue Star and others

Aryan Jakhar — Fri, 04 Nov 2022 02:58:49 +0000

The Nifty futures on the Singapore Exchange fell 7.5 points, or 0.04 percent, to 18,107, indicating that Dalal Street will open unchanged on Friday.

Q2 Result: Several companies will today disclose their Q2 financial results, including Britannia, Cipla, Titan Company, GAIL India, InterGlobe Aviation, Aditya Birla Fashion and Retail, Escorts Kubota, Go Fashion (India), Mahindra Logistics, Marico, TVS Motor Company, and Wockhardt.

Vodafone Idea: As a result of rising finance and operating costs, Vodafone India’s (Vi’s) net loss increased 6.4% on a year-over-year (YoY) basis to Rs 7,595 crore in the second quarter of FY23. The business reported a net loss of Rs 7,132 crore over the comparable period in the previous year.

Adani Enterprises: According to its results released on Thursday, the company’s consolidated net profit for the quarter ending in September (Q2) more than quadrupled from the prior year to reach Rs 461 crore. Consolidated sales for the company increased nearly threefold year over year (YoY) in the second quarter to reach Rs 38,175 crore.

Hero MotoCorp: Due to weaker rural demand, the company’s consolidated net profit decreased 8.63% year over year (YoY) to Rs 682.28 crore in the second quarter of FY23. In Q2 of FY22, the company generated a net profit of Rs. 747.79 crore.

Mahindra Lifespaces Developers: Compared to a net profit of Rs 6.52 crore in the same quarter last year, Mahindra Lifespaces Developers, the Mahindra Group’s real estate and infrastructure development division, posted a net loss of Rs 7.74 crore for the quarter that ended in September.

Amara Raja Batteries: The business reported a combined profit of Rs 201.22 crore, up 39% year over year. The quarter’s revenue increased 19.3% to Rs 2,700.5 crore.

Sanofi India: As a result of an unusual gain in the prior year, the company’s second-quarter earnings, at Rs. 130.9 crore, was down 75% YoY. For the quarter, revenue decreased 8.3% year over year to Rs 692 crore.

Blue Star: The business reported a combined profit of Rs. 43 crore, up 37% year over year. Its income increased by 27% to Rs 1,576 crore.

JK Lakshmi Cement: In the second quarter, the cement company’s consolidated earnings fell by 29% year over year to Rs. 61.8 crore. With respect to the same period previous year, its income increased by 13.6% to Rs 1,373.5 crore.

Ajanta Pharma: For Q2FY23, the business reported a 20% year-over-year fall in earnings at Rs 157 crore. Operating income increased 6% to Rs 938 crore.

Cochin Shipyard: A European Client has placed an international order with the business for two commissioning service operation vessels (CSOV). For the installation of offshore wind farms, these vessels will be employed. Approximately Rs 1,000 crore is the project’s anticipated cost.

SRF: The business has authorised plans for the construction of four new facilities and the expansion of an existing plant’s production capabilities, which are expected to cost Rs 604 crore in total.

Ceeta Industries: The business has started producing ready-to-eat snacks on a commercial scale.

Persistent Systems: The company has established a strategic agreement with Software AG to create joint solutions to speed up operational excellence through the modernization of processes and applications as well as the simpler movement of data between businesses to create value.